CEPI awards up to $14.1 million to IVI and Bharat Biotech to advance development of Chikungunya vaccine

(International Vaccine Institute) CEPI, the Coalition for Epidemic Preparedness Innovations, in collaboration with Ind-CEPI, has announced a new partnering agreement with a consortium comprising Bharat Biotech (BBIL) and the International Vaccine Institute (IVI) to advance the development of a Chikungunya vaccine. CEPI will provide the consortium with up to US $14.1 million for vaccine manufacturing and clinical development of a two-dose live-inactivated vaccine (BBV87) against Chikungunya.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news